You are here: Industry Insights > mabthera

News List

Polivy® with R-CHP significantly improves lymphoma outcomes europeanpharmaceuticalreview
August 10, 2021
Polivy with MabThera/Rituxan and R-CHP is the first regimen in 20 years to improve significantly outcomes in a previously untreated form of lymphoma, Phase III study shows.
Pfizer wins EU approval for MabThera biosimilar pharmatimes
April 03, 2020
Pfizer has bagged European approval for Ruxience (rituximab), a monoclonal antibody (mAb) and biosimilar to MabThera (rituximab).
EC approves Roche’s MabThera for a rare autoimmune disease biospectrumasia
March 19, 2019
MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease in more than 60 years
Roche's MabThera garners EU clearance as first biologic therapy for pemphigus vulgaris firstwordpharma
March 15, 2019
The FDA approved MabThera in June last year for the treatment of patients with PV.
Pfizer's biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018 pharmafile
December 07, 2018
Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new data for its biosimilar version of Genentech’s
Green light for Roche/AbbVie's chemo-free CLL treatment combo pharmatimes
November 05, 2018
Roche says a combination of Venclyxto and MabThera has been approved in the European Union for people with previously treated chronic...